Another small clinical study investigated how gut microbiota affects the anti-tumor activity of the combination therapy with cetuximab (an anti-EGFR monoclonal antibody) and avelumab (an anti-PD-L1 monoclonal antibody) in patients with metastatic CRC. The gene discussed is CD274; the disease is neoplasm.